PDI loses another pharma contract

Share this article:
Contract sales provider PDI said Sanofi-Aventis would end its $20 million sales agreement with the firm, effective Dec. 1. It was set to expire Dec. 31, PDI said.

The end of the firm's Sanofi-Aventis deal comes a month after GlaxoSmithKline decided not to renew a $65 million to $70 million contract with PDI for 2007.

In April, AstraZeneca also ended a $65 million-$70 million agreement with PDI, affecting approximately 800 field reps.

PDI “has been significantly impacted” as the world's top pharma companies re-evaluate their commercial models, CEO Michael Marquad said in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.